Advancements in Therapeutic Approaches for Proliferative Vitreoretinopathy: A Comprehensive Review

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Sep 2

PMID 39219934

Authors

Kasturi K Dhawale

Pravin Tidake

Affiliations

Soon will be listed here.

Abstract

Proliferative vitreoretinopathy (PVR) is a significant complication of retinal detachment surgery, characterized by the growth of fibrous membranes that can lead to recurrent retinal detachment and vision loss. This comprehensive review aims to summarize the latest advancements in the therapeutic approaches for PVR, encompassing historical perspectives, current surgical techniques, pharmacological interventions, biological and genetic therapies, and novel experimental treatments. Traditional surgical methods, such as vitrectomy, have been refined with advanced instrumentation and techniques to improve outcomes. Pharmacological treatments, including anti-inflammatory and anti-proliferative agents, are being explored to prevent and manage PVR. Emerging therapies, such as stem cell and gene therapy, offer promising new avenues for treatment. Despite these advancements, challenges remain in preventing recurrence and improving long-term outcomes. This review highlights the progress made and identifies areas for future research, emphasizing the importance of continued innovation to enhance patient care and reduce the burden of PVR.

Citing Articles

The Role of Adjunctive Triamcinolone Acetonide in Post-traumatic Vitreoretinal Surgery: Current Insights and Future Perspectives.

Gandhi A, Daigavane S Cureus. 2024; 16(10):e71040.

PMID: 39525235 PMC: 11543381. DOI: 10.7759/cureus.71040.

References

Charteris D, Sethi C, Lewis G, Fisher S . Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye (Lond). 2002; 16(4):369-74. DOI: 10.1038/sj.eye.6700194. View

Di Lauro S, Kadhim M, Charteris D, Pastor J . Classifications for Proliferative Vitreoretinopathy (PVR): An Analysis of Their Use in Publications over the Last 15 Years. J Ophthalmol. 2016; 2016:7807596. PMC: 4939352. DOI: 10.1155/2016/7807596. View

Lumi X, Confalonieri F, Ravnik-Glavac M, Goricar K, Blagus T, Dolzan V . Inflammation and Oxidative Stress Gene Variability in Retinal Detachment Patients with and without Proliferative Vitreoretinopathy. Genes (Basel). 2023; 14(4). PMC: 10137369. DOI: 10.3390/genes14040804. View

Patra J, Das G, Fraceto L, Campos E, Del Pilar Rodriguez-Torres M, Acosta-Torres L . Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018; 16(1):71. PMC: 6145203. DOI: 10.1186/s12951-018-0392-8. View

Restrepo J, Duenas D, Corredor Z, Liscano Y . Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment. Cancers (Basel). 2023; 15(13). PMC: 10340640. DOI: 10.3390/cancers15133474. View

Petrie J, Guzik T, Touyz R . Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018; 34(5):575-584. PMC: 5953551. DOI: 10.1016/j.cjca.2017.12.005. View

Lehar J, Krueger A, Avery W, Heilbut A, Johansen L, Price E . Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 2009; 27(7):659-66. PMC: 2708317. DOI: 10.1038/nbt.1549. View

Nagpal M, Juneja R, Talati S . Managing PVR in the Era of Small Gauge Surgery. J Ophthalmol. 2021; 2021:8959153. PMC: 8665895. DOI: 10.1155/2021/8959153. View

Lopez J, Banerji U . Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol. 2016; 14(1):57-66. PMC: 6135233. DOI: 10.1038/nrclinonc.2016.96. View

10.

Ghasemi Falavarjani K, Hashemi M, Modarres M, Hadavand Khani A . Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy. Eye (Lond). 2014; 28(5):576-80. PMC: 4017106. DOI: 10.1038/eye.2014.21. View

11.

Idrees S, Sridhar J, Kuriyan A . Proliferative Vitreoretinopathy: A Review. Int Ophthalmol Clin. 2018; 59(1):221-240. PMC: 6310037. DOI: 10.1097/IIO.0000000000000258. View

12.

Lin Y, Ren X, Chen Y, Chen D . Interaction Between Mesenchymal Stem Cells and Retinal Degenerative Microenvironment. Front Neurosci. 2021; 14:617377. PMC: 7859517. DOI: 10.3389/fnins.2020.617377. View

13.

Banerjee P, Quartilho A, Bunce C, Xing W, Zvobgo T, Harris N . Slow-Release Dexamethasone in Proliferative Vitreoretinopathy: A Prospective, Randomized Controlled Clinical Trial. Ophthalmology. 2017; 124(6):757-767. DOI: 10.1016/j.ophtha.2017.01.021. View

14.

Heffer A, Wang V, Libby R, Feldon S, Woeller C, Kuriyan A . Salinomycin inhibits proliferative vitreoretinopathy formation in a mouse model. PLoS One. 2020; 15(12):e0243626. PMC: 7751870. DOI: 10.1371/journal.pone.0243626. View

15.

Wang Y, Tan H, Hui X . Biomaterial Scaffolds in Regenerative Therapy of the Central Nervous System. Biomed Res Int. 2018; 2018:7848901. PMC: 5899851. DOI: 10.1155/2018/7848901. View

16.

Roden D, Wilke R, Kroemer H, Stein C . Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011; 123(15):1661-70. PMC: 3093198. DOI: 10.1161/CIRCULATIONAHA.109.914820. View

17.

Tersi N, Kassumeh S, Ohlmann A, Strehle L, Priglinger S, Hartmann D . Pharmacological Therapy of Proliferative Vitreoretinopathy: Systematic Comparison of 36 Pharmacological Agents. J Ocul Pharmacol Ther. 2023; 39(2):148-158. DOI: 10.1089/jop.2022.0078. View

18.

Mithany R, Aslam S, Abdallah S, Abdelmaseeh M, Gerges F, Mohamed M . Advancements and Challenges in the Application of Artificial Intelligence in Surgical Arena: A Literature Review. Cureus. 2023; 15(10):e47924. PMC: 10613559. DOI: 10.7759/cureus.47924. View

19.

Dai Y, Dai C, Sun T . Inflammatory mediators of proliferative vitreoretinopathy: hypothesis and review. Int Ophthalmol. 2020; 40(6):1587-1601. PMC: 7242233. DOI: 10.1007/s10792-020-01325-4. View

20.

Charteris D . Proliferative vitreoretinopathy: revised concepts of pathogenesis and adjunctive treatment. Eye (Lond). 2019; 34(2):241-245. PMC: 7002479. DOI: 10.1038/s41433-019-0699-1. View